Athersys Inc. (NASDAQ:ATHX) has received a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that cover the stock, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy recommendation. Athersys’ rating score has improved by 40.1% from three months ago as a result of a number of analysts’ ratings changes.
Brokerages have set a 1 year consensus price objective of $6.00 for the company and are forecasting that the company will post ($0.11) EPS for the current quarter, according to Zacks. Zacks has also given Athersys an industry rank of 109 out of 265 based on the ratings given to related companies.
Several brokerages have issued reports on ATHX. Zacks Investment Research cut shares of Athersys from a “buy” rating to a “hold” rating in a research note on Tuesday. Maxim Group reissued a “buy” rating and issued a $10.00 price objective on shares of Athersys in a research note on Wednesday, September 28th.
Athersys (NASDAQ:ATHX) traded down 0.94% during trading on Wednesday, hitting $2.10. 365,754 shares of the stock traded hands. Athersys has a 52-week low of $0.94 and a 52-week high of $2.90. The stock’s market cap is $178.46 million. The company’s 50 day moving average price is $2.00 and its 200-day moving average price is $2.17.
Athersys (NASDAQ:ATHX) last announced its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.02. The company had revenue of $0.60 million for the quarter, compared to analysts’ expectations of $0.32 million. Athersys had a negative net margin of 18.89% and a negative return on equity of 25.42%. Athersys’s revenue was up 200.0% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.05) EPS. Equities research analysts forecast that Athersys will post ($0.20) earnings per share for the current fiscal year.
In other news, EVP John J. Harrington sold 15,000 shares of the company’s stock in a transaction on Friday, September 16th. The shares were sold at an average price of $1.96, for a total transaction of $29,400.00. Following the transaction, the executive vice president now directly owns 619,639 shares of the company’s stock, valued at approximately $1,214,492.44. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 10.90% of the company’s stock.
Several institutional investors have recently bought and sold shares of the company. NEXT Financial Group Inc boosted its position in Athersys by 1.4% in the second quarter. NEXT Financial Group Inc now owns 92,750 shares of the biopharmaceutical company’s stock worth $201,000 after buying an additional 1,250 shares during the period. A.R.T. Advisors LLC boosted its stake in shares of Athersys by 2.5% in the second quarter. A.R.T. Advisors LLC now owns 69,953 shares of the biopharmaceutical company’s stock worth $151,000 after buying an additional 1,715 shares during the last quarter. Alambic Investment Management L.P. boosted its stake in shares of Athersys by 164.3% in the second quarter. Alambic Investment Management L.P. now owns 56,300 shares of the biopharmaceutical company’s stock worth $122,000 after buying an additional 35,000 shares during the last quarter. Nationwide Fund Advisors acquired a new stake in shares of Athersys during the second quarter worth approximately $104,000. Finally, Rhumbline Advisers acquired a new stake in shares of Athersys during the second quarter worth approximately $161,000. 17.76% of the stock is currently owned by institutional investors and hedge funds.
Athersys Company Profile
Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Athersys Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys Inc. and related companies with MarketBeat.com's FREE daily email newsletter.